

## VIRTUAL MEETING INVITATION

**Pharmacy Proactively Adopting the COVID-19 LFD Service for Your Local Patients**

**Wednesday 30<sup>th</sup> April 2025**  
**13:10 – 13:45**  
or  
**19:25 – 20:00**

*The Adverse Event reporting statement and Prescribing Information for Pfizer medicines that will be referenced at the meeting can be found at the end of this document. This document is intended to be read electronically.*

Paxlovid® ▼ (nirmatrelvir/ritonavir) has a Conditional Marketing Authorisation (CMA) in the United Kingdom. A Conditional Marketing Authorisation means that further evidence on this medicinal product is awaited. New information on this medicinal product will be reviewed when any relevant information of significance becomes available and at least every year and the product information will be updated as necessary.<sup>1</sup>

Dear Healthcare Professional,

You are invited to attend a promotional meeting organised and funded by Pfizer Ltd which will include reference to Pfizer medicines relevant to the agenda topics. This meeting is intended for healthcare professionals resident in the United Kingdom. The virtual platform for this meeting is MS Teams. **This invitation is for your personal use. Please do not forward to others.**

### PFIZERPRO EVENTS:

If you wish to keep up to date with other Pfizer organised promotional educational meetings in your area that may be of interest to you as a healthcare professional resident in the UK, [please click here](#)

### EVENT AGENDA – LUNCH MEETING

13:05 - 13:10	<b>Joining and Registration</b>
13:10 - 13:15	<b>Welcome and Introduction</b> Leigh-ann Ogborne
13:15 - 13:45	<b>COVID-19 Management: From Patient Identification to Treatment Selection</b> <b>- The LDF Service: Top Tips on Implementation</b> Julia Powell
13:45	<b>Meeting Close</b>

### HOSTED BY

**Leigh-ann Ogborne**  
Healthcare Partnership Manager  
Pfizer Ltd

### SPEAKER

**Julia Powell**  
Chief Executive Officer  
Community Pharmacy Surrey and Sussex

OR:

### EVENT AGENDA – EVENING MEETING

19:20 - 19:25	<b>Joining and Registration</b>
19:25 - 19:30	<b>Welcome and Introduction</b> Leigh-ann Ogborne
19:30 - 20:00	<b>COVID-19 Management: From Patient Identification to Treatment Selection</b> <b>- The LDF Service - Top Tips on Implementation</b> Julia Powell
20:00	<b>Meeting Close</b>

*This promotional meeting is organised and funded by Pfizer Ltd. Please note that, under the law and the ABPI Code of Practice, Pfizer may only provide hospitality and/or promote its medicines to members of the healthcare professions and other relevant decision makers. Therefore, no unqualified person (e.g., medical students, non-medical spouses, partners) may be invited to or attend Pfizer meetings.*

*The meeting will be broadcast via a virtual platform enabling you to join the meeting from your own computer or mobile device and will allow you to receive audio and video streaming of the speaker presentations and pose questions to the speakers. You should not need to download any additional software onto your computer or mobile device in order to access the meeting however this is dependent on the device you are using. We ask that you ensure that you are in a private location when joining the virtual meeting and that no unqualified persons or members of the public are able to hear or view the meeting content.*

**REGISTER TO ATTEND:**

**Register to attend the meeting on the Pfizer Pro events site:**

**[30APR25 PfizerPro Event](#)**

**Reply by email or telephone to: Leigh-ann Ogborne - [leigh-ann.ogborne@pfizer.com](mailto:leigh-ann.ogborne@pfizer.com)**

**- 07989 222508 to confirm your attendance at this meeting.**

**Please include the meeting date and time in your response and provide an email address for Joining Instructions to be sent to you.**

**Adverse events should be reported.**

**Reporting forms and information can be found at <https://coronavirus-yellowcard.mhra.gov.uk> or search for MHRA Yellow Card in the Google Play or Apple App Store.**

**Adverse events should also be reported to Pfizer Medical Information on 01304 616161.**

Reference:

1. PAXLOVID UK Summary of Product Characteristics. Pfizer Inc.

**Prescribing Information (PI) for Paxlovid® ▼ (nirmatrelvir, ritonavir) [Click here](#)**

*Your personal data that you provide to us will be processed by Pfizer for the purpose of managing your attendance at the meeting. We will share your personal data with our nominated agency who manage[s] our meeting registration and is under an obligation to process your personal data only for that purpose. To find out more about how Pfizer processes your personal data, including public disclosures of the transfers of value that you may receive from Pfizer, please refer to the Pfizer HCP Privacy Notice at <https://privacycenter.pfizer.com/en/hcp> If you have questions about our Privacy Notice, or if you would like to exercise any individual rights for example to review, correct, update, suppress, restrict or delete personal data that you have provided to us, or to opt out of any communications, please contact us at [DataProtectionUK@Pfizer.com](mailto:DataProtectionUK@Pfizer.com) or write to the following address: Pfizer Limited, IPC 1-1, Walton Oaks, Dorking Road, Tadworth, Surrey KT20 7NS.*